[14C]-rencofilstat 225mg

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NASH With Fibrosis

Conditions

NASH With Fibrosis

Trial Timeline

Mar 1, 2023 → Aug 4, 2023

About [14C]-rencofilstat 225mg

[14C]-rencofilstat 225mg is a phase 1 stage product being developed by Hepion Pharmaceuticals for NASH With Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05737433. Target conditions include NASH With Fibrosis.

What happened to similar drugs?

0 of 5 similar drugs in NASH With Fibrosis were approved

Approved (0) Terminated (1) Active (4)
🔄IVA337 + PlaceboInventivaPhase 3
🔄MGL-3196 + PlaceboMadrigal PharmaceuticalsPhase 3
🔄Resmetirom + PlaceboMadrigal PharmaceuticalsPhase 3
Elafibranor + PlaceboGenfitPhase 3
🔄Aramchol free acid + PlaceboGalmed PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05737433Phase 1Completed

Competing Products

20 competing products in NASH With Fibrosis

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
AZD2693AstraZenecaPhase 1
29
AZD4076 + PlaceboAstraZenecaPhase 1
29
LIK066 + PlaceboNovartisPhase 2
35
Tropifexor (LJN452) + Cenicriviroc (CVC)NovartisPhase 2
35
Tropifexor + LicogliflozinNovartisPhase 2
27
LMB763 + PlaceboNovartisPhase 2
27
Tropifexor (LJN452) + PlaceboNovartisPhase 2
27
TRO19622 + PlaceboRochePhase 2
35
SEL + SIMGilead SciencesPhase 2
35
Seladelpar + PlacebosGilead SciencesPhase 2
27
Placebo + SIMGilead SciencesPhase 2
27
CilofexorGilead SciencesPhase 1
29
Firsocostat + FenofibrateGilead SciencesPhase 1
29